Johannes Gerardus Chri Schikan Sells 29,070 Shares of Pharvaris (NASDAQ:PHVS) Stock

Key Points

• Insider sale: Director Johannes Gerardus Chri Schikan sold 29,070 shares on April 30 at an average of $30.32 for $881,402, and sold a total of 40,000 shares in late April for about $1.21 million, leaving him with 355,167 shares (≈ $10.77M).
• Stock action: PHVS traded at $29.44 (down $1.57) with volume 512,191 versus an average of 245,049; the 50-day and 200-day moving averages are $27.62 and $26.03, respectively, and the 1-year range is $14.59–$31.14.
• Analyst and company snapshot: Pharvaris is a clinical-stage biopharma developing oral therapies for hereditary angioedema (lead program PHA121); analysts collectively rate the stock a Moderate Buy with an average price target of $42.73 (11 Buys, 2 Holds, 1 Sell).

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Johannes Gerardus Chri Schikan sold 29,070 shares of the company's stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the transaction, the director directly owned 355,167 shares in the company, valued at $10,768,663.44. The trade was a 7.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The shares were sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Stock Performance

NASDAQ PHVS traded down $1.57 on Friday, reaching $29.44. The stock had a trading volume of 512,191 shares, compared to its average volume of 245,049. The business has a 50 day moving average price of $27.62 and a 200 day moving average price of $26.03. Pharvaris N.V. has a 1 year low of $14.59 and a 1 year high of $31.14.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its earnings results on Friday, April 3rd. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). Analysts anticipate that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharvaris

Large investors have recently made changes to their positions in the business. Tudor Investment Corp ET AL acquired a new position in shares of Pharvaris during the 3rd quarter worth about $1,943,000. Patient Square Capital LP lifted its position in shares of Pharvaris by 41.4% during the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company's stock worth $8,617,000 after purchasing an additional 101,098 shares during the last quarter. Boothbay Fund Management LLC lifted its position in shares of Pharvaris by 735.1% during the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company's stock worth $3,373,000 after purchasing an additional 118,994 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 710.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company's stock worth $676,000 after purchasing an additional 23,743 shares during the last quarter. Finally, General Atlantic L.P. lifted its position in shares of Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock worth $200,380,000 after purchasing an additional 500,000 shares during the last quarter.

Wall Street Analyst Weigh In

PHVS has been the topic of a number of recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wolfe Research assumed coverage on Pharvaris in a research note on Thursday, April 9th. They set an "outperform" rating and a $42.00 price target for the company. Citigroup reiterated a "buy" rating on shares of Pharvaris in a research note on Wednesday, April 15th. Wedbush upped their price target on Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pharvaris currently has an average rating of "Moderate Buy" and an average price target of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.